Screener
NewAmsterdam Pharma Company NAMS Change In Fair Value Of Earnout
Change In Fair Value Of Earnout at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept nams:ChangeInFairValueOfEarnout.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210272
| Line item | For the three months ended March 31, 2026 | For the three months ended March 31, 2025 |
|---|---|---|
| Operating loss | (58,420) | (68,925) |
| Other income (expense): | ||
| Interest income | 5,650 | 7,351 |
| Fair value change – earnout | — | 3,992 |
| Fair value change – warrants | 5,942 | 13,762 |
| Foreign exchange gains/(losses) | (1,613) | 4,293 |
| Loss before tax | (48,441) | (39,527) |
| Income tax expense | — | — |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's change in fair value of earnout?
- NewAmsterdam Pharma Company (NAMS) reported change in fair value of earnout of -$3.99M in Q1 2025.
- How has NewAmsterdam Pharma Company's change in fair value of earnout changed year-over-year?
- NewAmsterdam Pharma Company's change in fair value of earnout decreased by 145.9% year-over-year, from $8.7M to -$3.99M.
- What is the long-term trend for NewAmsterdam Pharma Company's change in fair value of earnout?
- Over 2 years (2022 to 2024), NewAmsterdam Pharma Company's change in fair value of earnout has grown at a 623.5% compound annual growth rate (CAGR), from $707K to $37.01M.
- What does change in fair value of earnout mean?
- Change In Fair Value Of Earnout as reported by NewAmsterdam Pharma Company N.V. Ordinary Shares.
Ask your AI about NewAmsterdam Pharma Company's change in fair value of earnout.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude